If I Were Your Health Coach: What I’d Want You to Know About GLP-1s and Weight Loss Medication
GLP-1 medications can be genuinely powerful tools. What often gets left out of the conversation though is how to protect your health while using them and what to think about before, during, and after.
This isn’t about whether you should or shouldn’t take them. That’s a conversation for you and your doctor. This is about the information that helps you make the most of whatever you decide.
First, A Note on What This Is
As a health coach, my job is not to tell you what to do. It never is. My role is to ask good questions, share information that might be useful, and help you think through your options so you can make decisions that genuinely work for you.
GLP-1 medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others in this class — are among the most discussed health topics of the last several years, and for good reason. They produce meaningful weight loss for many people, and that weight loss can carry real health benefits. They are also medications with mechanisms, side effects, and long-term considerations that deserve a thorough, honest conversation.
What follows is what I would want you to know if we were working together. Not to push you in any direction. To make sure you have the full picture including the parts that often do not make it into the conversation with your prescriber.
What GLP-1 Medications Actually Do
GLP-1 receptor agonists work primarily by mimicking glucagon-like peptide-1, a hormone naturally released after eating. They slow gastric emptying, reduce appetite, increase feelings of fullness, and in the case of dual agonists like tirzepatide, also act on GIP receptors to further influence metabolism and fat storage.
The result for many people is significant: reduced hunger, reduced food intake, reduced food noise, and substantial weight loss. Clinical trials have shown average weight loss of 15% or more of body weight with the higher-dose formulations. For people whose weight is affecting their health with conditions like cardiovascular disease risk, type 2 diabetes, sleep apnea, and joint health they can be a meaningful intervention.
But here is the question worth asking, and one I would explore with any client:
What do you understand about what happens to your body during this process… and what happens if and when the medication changes?
Because the weight loss itself is only part of the story. What is lost, how it is lost, and what happens after are also parts that require serious attention.
The Muscle Problem: What You’re Losing Along With the Fat
One of the most important, and least-discussed, aspects of GLP-1-induced weight loss is where the weight loss is coming from: body fat? muscle? both?
When we lose weight rapidly, the body does not discriminate neatly between fat tissue and lean tissue. Research shows that with semaglutide, approximately 25% of total weight lost comes from lean body mass — meaning muscle. Some studies have reported even higher figures, with up to 40% of total weight lost coming from lean mass in certain populations.
In some studies, weight loss of greater than 10 kg has been described with semaglutide and tirzepatide, with up to 40% of total weight lost from lean body mass. Loss of lean body mass could be particularly worrisome for those at high risk for frailty and sarcopenia, both of which are associated with increased morbidity, hospitalizations, reduced quality of life, disability, and mortality.
Why does this matter? Muscle is not just a fitness concern. It is a metabolic organ. It is your primary site of glucose disposal, which means losing muscle mass simultaneously worsens the metabolic health you may be trying to improve. It is also the tissue that determines your strength, your functional capacity, your injury risk, and your metabolic rate over time.
Someone who loses 30 pounds on a GLP-1 medication, with 7 to 10 of those pounds being muscle, has not achieved the same metabolic outcome as someone who lost 30 pounds of fat while preserving muscle. The scale looks the same. The body composition is significantly different. And the long-term metabolic trajectory is significantly different.
The good news: muscle loss on GLP-1s is not inevitable. The research is increasingly clear that resistance training and adequate protein intake during the weight loss period can substantially preserve lean mass. But this does not happen automatically, it requires deliberate, structured effort.
This is one of the areas where working with a coach alongside your prescriber makes a real difference. The medication can help with appetite and weight loss. Building the habits that protect your muscle while that happens is a different kind of work and it is work worth doing for your long-term health success.
Questions worth sitting with:
Am I currently strength training during this weight loss period?
Am I eating enough protein to support muscle preservation targeting at least 0.7 to 1 gram per pound of body weight daily?
Do I know what my current body composition looks like, not just my weight?
The Bone Question: What the Research Is Starting to Show
This is the area where the science is still developing and where I think people deserve a more direct conversation than they are typically getting to make well informed decisions on their weight loss strategies.
A 2024 randomized controlled trial found that semaglutide reduced hip bone mineral density by 2.6% and lumbar spine density by 2.1% over 52 weeks. A large population analysis found that about 4% of GLP-1 users developed osteoporosis compared with just over 3% of non-users — a roughly 30% increased risk. Among patients without type 2 diabetes who maintained stable weight on a GLP-1, osteoporosis risk was 22% higher than in comparable patients on other weight loss approaches.
A 2025 study also found that patients taking tirzepatide had a notably higher risk of osteoporosis and fractures than those taking other GLP-1s. This is consistent with the pattern that greater weight loss appears to drive greater bone loss.
Here is the important nuance: the research is not entirely consistent, and for people with type 2 diabetes specifically, some studies have found that GLP-1s may actually be protective for bone health. Context matters enormously here: your age, your diabetes status, your baseline bone density, your menopausal status if applicable, and how much weight you lose all factor into your individual risk profile.
What is consistent across the research: the degree of weight loss appears to be the primary driver of skeletal risk. The faster and more significant the weight loss, the more pronounced the bone response tends to be.
What is also consistent: exercise significantly mitigates this risk. A 2024 clinical trial published in JAMA Network Open examined three groups: exercise only, GLP-1 medication only, and GLP-1 medication plus exercise. The results were striking:
GLP-1 medication alone: bone density declined at the hip and spine
Exercise alone: bone density was preserved while still losing weight
GLP-1 medication plus exercise: greatest weight loss and preserved bone density
The combination of medication plus structured exercise produced the best outcome across every measure studied.
Questions worth sitting with:
Do I know my current bone density baseline?
Am I including weight-bearing and resistance exercise? Both of which protect bone.
Has my prescriber discussed bone health monitoring with me during this treatment?
Am I getting enough calcium and vitamin D to support bone health during this period?
The Off-Ramp Question: What Happens When You Stop?
This is the part of the GLP-1 conversation tends to get the least attention prior to starting weight loss medication but it critical because the considerations and carry some of the most significant implications for long-term health.
Prescribers vary widely in how they approach duration of treatment. Some frame GLP-1s as a short-term intervention to initiate weight loss. Others frame them as a long-term or indefinite maintenance medication. The reality is that this conversation often does not happen clearly enough and many people find themselves either staying on the medication indefinitely without a defined plan, or stopping abruptly and experiencing significant weight regain without preparation.
The research so far on what happens when people stop GLP-1 medications is important to aid in informed decisions.
Research published in eClinicalMedicine found that GLP-1 cessation is associated with a predictable, decelerating pattern of weight regain with approximately 60% of the weight lost during treatment regained within one year of stopping. The regain is most rapid in the first three to four months after discontinuation. A separate review found that participants taking semaglutide or tirzepatide regained an average of 9.69 kg (approximately 21 lbs) after stopping.
It’s important to note: not everyone regains. A large Cleveland Clinic analysis of nearly 8,000 patients found that about 45% of patients in the obesity group maintained their weight or continued losing after discontinuation — often because they transitioned to other treatments or successfully sustained lifestyle changes. This is where working with an RD, fitness trainer, and/or health coach can be valuable for sustainable change.
What is less nuanced is this: the weight regain that does occur after stopping GLP-1s comes back as fat, not as the muscle that may have been lost during the weight loss phase. This means the body composition picture often looks worse post-medication than it would have if the weight had been maintained through lifestyle alone, particularly if muscle preservation was not prioritized during the loss phase.
The medications suppress appetite artificially. When they stop, appetite often returns and if habits have not been built during the weight loss period to regulate eating independently of that appetite suppression, the recurrence of hunger can feel overwhelming.
This isn’t a reason not to use the medication. It’s a very good reason to use the time on the medication deliberately: to build the habits, the movement patterns, the nutrition practices, and the relationship with food that can sustain your health whether or not you continue the medication.
Questions worth sitting with:
Have I had a conversation with my prescriber about what the plan looks like long-term?
Do I have a defined vision of what my health looks like after medication, not just during it?
Am I using this window to build habits, or relying primarily on the medication to do the work?
What would I want to have in place before I consider stepping down or stopping?
The Long-Term Health Considerations
I want to be careful here to stay in my lane as a health coach: the long-term safety profile of GLP-1 medications is a medical conversation that belongs with your physician. What I can share is what the questions are, so you can have an informed conversation with your prescriber.
Questions worth raising with your doctor:
Thyroid: The FDA label for semaglutide includes a warning regarding thyroid C-cell tumors observed in animal studies. Ask your prescriber what this means for your individual risk profile and monitoring.
Pancreatitis: A rare but serious potential side effect. Ask about your personal risk factors and what symptoms to watch for.
Gallbladder: Rapid weight loss of any kind increases gallstone risk. GLP-1-induced weight loss is no exception.
Cardiovascular: For people with existing cardiovascular disease, GLP-1s have shown cardiovascular benefits in major trials. For others, the picture is more nuanced. Know where you stand.
Long-term unknown: These medications, at current doses and formulations, have not been on the market long enough to have decades of long-term safety data. That’s not necessarily alarming as many medications are appropriately used before long-term data exists, but it is worth factoring into your thinking.
None of this is to create fear. It’s to ensure you are asking the questions that allow you to make a genuinely informed decision.
Use the Weight Loss Window to Build Better Habits
If there is one reframe I would offer to anyone on a GLP-1 medication, it is this:
The medication suppresses appetite. It does not build habits.
The reduced hunger you experience on a GLP-1 is real and valuable: it creates space to make different choices without fighting the biology of intense hunger. But that space is temporary if the habits are not being built simultaneously.
The window of reduced appetite is an opportunity to practice eating differently, moving regularly, sleeping adequately, managing stress, and hydrating well. Those habits are what carry you forward if and when the medication changes.
The habits are the insurance policy and the medication is the tool that makes building them more accessible.
Here is what I would focus on during any GLP-1 weight loss period:
Nutrition:
Prioritize protein at every meal.
25 to 40 grams per meal, targeting at least 0.7 to 1 gram per pound of body weight daily.
On a reduced appetite, it is easy to undereat protein specifically because high-protein foods require more effort to consume than high-carbohydrate options. Protein intake directly protects muscle mass, supports bone health, stabilizes blood sugar, and sustains satiety.
Do not let reduced appetite translate to nutritional neglect. Eating less and eating poorly are not the same strategy.
Movement:
Resistance training is the single most important exercise intervention during GLP-1-induced weight loss for muscle preservation, bone protection, metabolic health, and long-term weight maintenance.
Two to four sessions per week of progressive resistance exercise, combined with regular walking and daily movement, is the evidence-based standard.
Walking specifically is worth emphasizing: it is weight-bearing (which protects bone), it supports cardiovascular health, it is accessible regardless of fitness level, and it has a meaningful impact on blood sugar regulation and stress management.
Sleep:
Sleep deprivation drives ghrelin elevation (aka the hunger hormone) and cortisol elevation, both of which work against weight management and metabolic health.
The appetite suppression of GLP-1s does not fully override the hunger effects of poor sleep.
Prioritize getting 7 to 9 hours of quality sleep per night. It’s an important and functional part of any weight loss or metabolic health strategy.
Stress management:
Chronic cortisol promotes visceral fat storage, drives insulin resistance, and triggers cravings for high-reward foods.
Managing the stress load during weight loss matters, not just for wellbeing, but for the metabolic outcomes the medication is trying to support.
Hydration:
GLP-1s slow gastric emptying and reduce overall intake and both can reduce natural hydration cues.
Prioritize deliberate hydration targeting at least half your body weight in ounces of water daily to support kidney function, digestion, energy, and cognitive clarity during the weight loss period.
What I Would Ask You
As a coach, my role is not to tell you what to decide. It is to make sure the decision, whatever it is, is an informed one.
If we were working together and you brought GLP-1 medications to our conversation, here is what I would explore with you:
What is your goal here and what does success look like to you beyond the number on the scale?
What do you know about what is happening to your body composition during this process, and what do you want to protect?
Have you talked with your prescriber about bone health monitoring and what that plan looks like?
What healthy habits are you building during this period that will serve you after it?
Do you have a vision of what maintenance looks like and have you had that conversation with your doctor?
What habits feel most important to you to have solidly in place before considering stepping down from the medication?
There are no right or wrong answers to these questions. They are the questions that help you use this tool as intentionally as possible for your long-term health, not just your short-term weight.
Final Thoughts
GLP-1 medications are not a magic solution. They are a powerful pharmacological tool that, used thoughtfully and with the right support, can produce meaningful health outcomes for the right person.
What they cannot do is:
Replace the work of building a body and a life that supports your health long-term.
Build the muscle you will need as you age.
Protect your bones without the exercise and nutrition that do that work.
Install the habits that sustain your weight and your health when the appetite suppression lifts.
That work is yours.
Navigating a GLP-1 journey and want support building the habits, the movement foundation, and the nutrition practices that protect your health and sustain your results?
This is exactly where coaching makes a real difference… alongside your medical team, not in place of it.
Article References
The sources cited in the article:
Drug Topics (DT) "How GLP1 Therapies Could Impact Bone Density, Muscle Loss.” DT - GLP1 Therapies and Bone Density, Muscle Loss
Healthline. “What to Know About GLP-1 Medications and Bone Health.” Healthline - GLP-1 Medications and Bone Health
Cleveland Clinic (CC). “What Happens When Patients Stop Taking GLP-1 Drugs?” CC - When Patients Stop Taking GLP-1 Drugs
Healthline. "Can GLP-1s Cause Long-term Side Effects?” Healthline - Can GLP-1s Cause Long-term Side Effects?
NPR. “Some Who Take GLP-1s are Suffering Serious Side Effects.” NPR - Some Who Take GLP-1s are Suffering Serious Side Effects
